BLUE - Spark Newswire

1 minute read

bluebird bio To Withdraw Marketing Authorization For SKYSONA From EU And Withdraw Marketing Applicatino For SKYSONA From MHRA

October 21, 8:39 AM

On October 21, 2021, bluebird bio, Inc. announced that as part of the winding down of its operations in Europe, it will withdraw its regulatory marketing authorization for SKYSONA from the European Union, and its

BLUE

4 minute read

bluebird bio Highlights Filing By Its 2seventy Bio Related To Spin Off

By Benzinga Newsdesk

October 8, 5:03 PM

bluebird bio, Inc. (NASDAQ:BLUE) today announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). This Form 10 reflects bluebird bio’s

BLUE

1 minute read

Analyst Ratings

What 6 Analyst Ratings Have To Say About bluebird bio

By Benzinga Insights

September 22, 12:34 PM

Analysts have provided the following ratings for bluebird bio (NASDAQ:BLUE) within the last quarter:

BLUE

1 minute read

Mizuho Maintains Buy on bluebird bio, Lowers Price Target to $23

By vishwanath@benzinga.com

September 22, 7:59 AM

Mizuho analyst Difei Yang maintains bluebird bio (NASDAQ:BLUE) with a Buy and lowers the price target from $29 to $23.

BLUE

6 minute read

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs

By Shanthi Rexaline

September 22, 7:45 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

ABEO

1 minute read

Bluebird Bio Files US Application For β-thalassemia Gene Therapy

By Vandana Singh

September 22, 7:03 AM

Bluebird Bio Inc (NASDAQ:BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel)…

BLUE